- Home
- TYRA vs GAM Comparison
TYRA vs GAM Comparison
Compare TYRA & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TYRA | GAM |
|---|---|---|
| Founded | 2018 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TYRA | GAM |
|---|---|---|
| Price | $29.72 | $60.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $40.75 | N/A |
| AVG Volume (30 Days) | ★ 611.8K | 20.1K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.74% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 11.67 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.42 | $37.32 |
| 52 Week High | $32.44 | $46.48 |
Technical Indicators
Market Signals| Indicator | TYRA | GAM |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 49.87 |
| Support Level | $29.51 | $60.30 |
| Resistance Level | $32.37 | $61.40 |
| Average True Range (ATR) | 2.01 | 0.80 |
| MACD | -0.31 | -0.05 |
| Stochastic Oscillator | 45.63 | 28.04 |
Price Performance
Historical ComparisonAbout TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.